Last Updated: 10 Nov 2024
Executive Summary
Genetic Technologies Ltd. (GENE) is a molecular diagnostics company that provides predictive testing and assessment tools for women's health. The company has a market capitalization of $3.78 billion and is headquartered in Fitzroy, Australia. GENE's latest stock price is $0.77.
Company Overview
GENE was founded in 1995 and has since become a leading provider of molecular diagnostics tests for women's health. The company's tests are used to assess the risk of developing breast cancer, ovarian cancer, and other genetic conditions. GENE also provides testing for prenatal screening and genetic counseling.
Fundamental Analysis
GENE's financial performance has been mixed in recent years. The company has reported losses in each of the past three fiscal years. However, revenue has grown steadily, and the company is expected to return to profitability in the near future.
GENE's key financial metrics are as follows:
Revenue: $96.7 million (TTM)
Gross profit: $60.1 million (TTM)
Operating income: -$10.8 million (TTM)
Net income: -$10.4 million (TTM)
EPS: -$0.02 (TTM)
Technical Analysis
GENE's stock price has been in a downtrend since early 2022. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is also below 50, indicating that the stock is oversold.
Short Term Outlook
The technical analysis suggests that GENE's stock price is likely to continue to decline in the short term. The stock is currently trading below its key moving averages and the RSI is oversold. However, the company's fundamentals are improving, and the stock could rebound if the company reports positive news in the near future.
Long Term Outlook
The long-term outlook for GENE is more positive. The company is a leader in the molecular diagnostics market, and its tests are used by clinicians around the world. The company's revenue is growing, and it is expected to return to profitability in the near future.
Analyst Recommendations
Analysts are mixed on GENE's stock. Some analysts believe that the stock is undervalued and has a lot of upside potential. Other analysts are more cautious, citing the company's history of losses. Overall, the consensus analyst rating for GENE is "hold."
